Nutriband Advances Abuse-Deterrent Transdermal Drug Technology with AVERSA Innovation
TL;DR
Nutriband's AVERSA technology enhances drug safety, offering a competitive advantage in the transdermal pharmaceutical market.
AVERSA technology integrates aversive agents into transdermal patches to prevent drug abuse and misuse, safeguarding patient access.
Nutriband's AVERSA technology promotes safe drug usage, improving patient care and reducing the risk of substance abuse.
Nutriband secures patents globally for AVERSA technology, partnering with Kindeva Drug Delivery to advance abuse-deterrent fentanyl patches.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc., a pharmaceutical development company, is making significant strides in creating safer transdermal drug delivery systems through its innovative AVERSA technology. The company's proprietary approach aims to address the critical challenge of drug abuse and misuse while ensuring patients retain access to necessary medications.
The AVERSA technology represents a potential breakthrough in pharmaceutical safety, with the ability to be incorporated into any transdermal patch. Its primary focus is on drugs with high abuse potential, particularly opioids like fentanyl. By integrating aversive agents into the patch design, the technology aims to prevent diversion, misuse, and accidental exposure.
Nutriband has demonstrated substantial commitment to this technology, securing a robust intellectual property portfolio with patent protections across multiple global markets, including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. This comprehensive patent strategy underscores the potential significance of the AVERSA technology in the pharmaceutical landscape.
The company recently completed a significant financing round, raising $8.4 million in April 2024 to support the commercial development of its AVERSA Fentanyl patch. This financial milestone was further bolstered by a strategic partnership with Kindeva Drug Delivery in February 2025, establishing a long-term exclusive collaboration to bring the technology to market.
The potential impact of AVERSA technology extends beyond individual product development. By creating a mechanism to deter drug abuse while maintaining therapeutic accessibility, Nutriband is addressing a critical public health challenge. Opioid misuse remains a significant global concern, and technologies that can mitigate risks without compromising patient care represent an important advancement in pharmaceutical innovation.
As the technology progresses, it could potentially serve as a model for other transdermal drug delivery systems, offering a scalable solution to reduce drug abuse risks across various pharmaceutical applications. The broad patent coverage and strategic partnerships position Nutriband as a potentially transformative player in the pharmaceutical safety and innovation space.
Curated from InvestorBrandNetwork (IBN)
